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ABSTRACT 
Introduction: To analyse the association between antihypertensive (anti-HT) drug use and risk of 
urothelial cancer (UC) death. UC occur as bladder cancer (BCa) and upper tract urothelial 
carcinomas (UTUCs). Hypertension is a suggested risk factor for BCa and may impair disease 
prognosis. However it`s unclear if use of anti-HT drugs could improve prognosis of UC. 
Materials and Methods: We evaluated the association between use of anti-HT drugs and UC 
survival among 14,065 participants diagnosed with BCa and 1080 with UTUC during 1995-2012 in 
Finland. We analyzed data using multivariable adjusted conditional Cox regression model. 
Results: Angiotensin-receptor (ATR) blocker use before BCa diagnosis was associated with slightly 
decreased risk of BCa death (HR: 0.81 CI: 0.71-0.93). The association was dose-dependent and it 
decreased in association with elevated intensity of ATR-blocker use.  
Post-diagnostic use of ATR-blockers was similarly associated with better survival compared to non-
users (HR: 0.81 CI: 0.71-0.92. Interestingly use of calcium-channel blockers associated also with 
better survival and the risk of BCa death decreased with increasing intensity of use (HR: 0.67 CI: 
0.52-0.86 for highest intensity). 
Conclusions: Our large population- based cohort suggests decreased risk of BCa death among ATR-
blocker and calcium-channel blocker users. The risk association among ATR-blockers and calcium-
channel blockers was dose-dependent suggesting a causal explanation. Similar risk associations 
are not observed for other anti-HT drug users which may suggest a direct effect of ATR blocker or 
calcium-channel blocker use. Further studies are needed to elucidate the potential anticancer 
mechanism. 
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INTRODUCTION 
Urothelial cancers (UC) can be divided into bladder cancer (BCa) and upper tract urothelial cancers 
(UTUCs). BCa is the ninth most common cancer in the world [1]. Low-grade BCa recurs often, 
requiring intense follow-up which makes it one of the most expensive cancers in the world. High-
grade BCa advances often to fatal stage causing high losses in life expectancy in the Western 
countries [2]. UTUCs account only for 5-10 % of urothelial carcinomas [3]. The yearly incidence of 
UTUC in the Western countries is estimated to be 2/100.000 [4]. Urothelial cancers are more 
common in men than women [1]. Smoking is the most important risk factor both for BCa and 
UTUC [5,6].  
Besides smoking, also other possible risk factors for UC have been suggested. Diabetes may 
increase the risk of BCa and BCa death as well as increase the risk of disease recurrence in UTUC 
[7,8]. Hypertension may be a risk factor for BCa and many other cancer types, but studies are few 
[9], and not all studies agree [10]. Hypertension may also impair disease prognosis [9]. Still it is 
unknown whether use of antihypertensive drugs (anti-HT drugs) would lower the risk of BCa or 
improve disease prognosis. A challenge is to separate influence of anti-HT medication from that of 
the underlying hypertension. Another challenge is to be able to take into account simultaneous 
use of different drug groups and different treatments when evaluating possible effect of a single 
drug group.  
Here we analyse BCa and UTUC-specific survival by use of different groups of antihypertensive 
drugs among participants with urothelial cancer in the bladder or the upper urinary tract.   
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MATERIALS AND METHODS 
Study cohorts 
Two study cohorts were identified from the Finnish Cancer Registry (FCR), which registers virtually 
all cancer diagnoses in Finland through mandatory notifications and pathological reports [11]. 
Causes of death in Cancer Registry are obtained from national mandatory death certificate 
registry. Causes of death reported by clinicians in death certificates are reviewed by medical 
authorities and in unclear cases a forensic examination of the cause of death is mandated. 
The BCa cohort consisted of 14,065 primary bladder cancer cases from Finland diagnosed during 
1995-2012.  Data contained information on the primary site of cancer, tumour extent at diagnosis 
(localized, locally advanced, advanced, unknown), date and method of diagnosis, primary 
treatment method (surgery, radical cystectomy, cytostatic drugs, chemotherapy, antihormonal 
therapy) and date and cause of death. Surgery includes radical cystectomies but also endoscopic 
operations such as partial removal of bladder and transurethral resection of tumour. 
The UTUC cohort consisted on 1,080 participants diagnosed with primary cancers in the renal 
pelvis or the ureter in Finland between 1995 and 2012. The data included same information as for 
the BCa cohort (surgery includes radical nephro-ureterectomy but also minor surgical 
operations). FCR does not record tumour grade, thus it was not available.   
Data on either cohort does not include tumour recurrences. 
Information on antihypertensive medication use 
Both study cohorts were linked to national prescription database for information on 
antihypertensive (anti-HT) medication use during 1995-2012. The database is maintained by the 
Finnish Social Insurance Institution (SII). SII provides reimbursements for physician-prescribed drug 
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purchases for every Finnish citizen in outpatient setting as a part of the national health insurance. 
The information on each purchase includes dose, purchase date, package size and number of 
packages bought.  
We identified each anti-HT drug by using drug-specific ATC-code (Table S1). Anti-HT drugs were 
categorised into five groups: angiotensin-converting enzyme (ACE)-inhibitors, angiotensin-
receptor (ATR)-blockers, diuretics, beta-blockers and calcium-channel blockers.  
Information on co-morbidities 
Both cohorts were linked to Care Registry (HILMO) maintained by the National Institute For Health 
And Welfare to collect information on diagnoses and procedures conducted in study population 
during 1995-2013. The Registry records all diagnoses and medical procedures from in- and 
outpatient hospital visits in Finland. Diagnoses recorded in HILMO were used to calculate Charlson 
co-morbidity index for each participant [12]. Conditions used in the index calculation are listed in 
Table S2. COPD and kidney failure diagnoses were added separately into analysis as they may 
serve as potential confounding factors. 
Statistical analysis 
We performed separate analyses for drug usage before and after UC diagnosis in both study 
cohorts. We compared the risk of BCa and UTUC death between users and non-users of anti-HT 
drugs.  
The total yearly mg amount of purchases of each anti-HT drug was calculated for each participant 
based on the dosing, package sizes and number of packages from each purchase. Total purchased 
yearly mg amount was divided by the dose corresponding to the drug specific Defined Daily Dose 
5
(DDD) for total number of DDDs purchased per year [13]. Each year with recorded purchases was 
considered as year of usage regardless of the amount purchased. 
Cumulative number of years for usage and DDDs was calculated separately for each year before 
and after UC diagnosis. Amount of use before the diagnosis was calculated by adding together all 
usage between 1995 and the year of diagnosis. We evaluated intensity of use by dividing 
cumulative amount of DDD with cumulative number of usage years. 
Post-diagnostic use was analysed as time-dependent variable to minimize immortal time bias. 
Time-dependent variables were formed by updating medication user status as well as cumulative 
amount, duration and intensity of use separately for each follow-up year after bladder 
cancer/UTUC diagnosis according to recorded purchases. Dose-dependence was evaluated by 
stratifying medication users by tertiles of DDD amount, duration and intensity of use based on the 
level reached on each follow-up year. After discontinuation of usage (full calendar year without 
any anti-HT drug purchases) the participants remained in the user category to minimize bias due 
to selective discontinuation of preventative medications in fatal stage of cancer. After 
discontinuation year cumulative tertiles of DDD amount, duration and intensity of anti-HT drug 
use remained the same level as before (no cumulative grow up after discontinuation).  
Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (95% Cis) 
for the risk of cancer-specific death. Time metric used was years and months since BCa or UTUC 
diagnosis. Follow up continued until death, emigration or the common closing date Dec 31st, 2012, 
whichever came first.  
Cox regression analyses were adjusted for age at diagnosis, year of diagnosis, tumor extent (local 
or advanced), surgery, cytostatic drugs, kidney failure, COPD, Charlson co-morbidity index and use 
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of statins, antidiabetic medication, non-steroidal anti-inflammatory drugs and aspirin during the 
follow-up.   
Simultaneous use of multiple anti-HT drug groups was modelled by forming separate time-
dependent variables for use of each drug group, i.e. ACE-inhibitors, ATR-blockers, beta-blockers, 
calcium channel blockers and diuretics. These variables were included in the Cox regression model 
together to model simultaneous use. 
Delayed association between anti-HT drug use and risk of cancer death was investigated in lag 
time analyses where the exposure was lagged forward in the follow-up time; analysing medication 
use that occurred one, three or five years before. 
The data were analysed using the IBM SPSS statistics 24 program. 
RESULTS 
Population characteristics 
Anti-HT drug use was very common in our bladder cancer cohort. Of the 14,065 participant 10,489 
(75 %) had used at least one anti-HT drug before or after diagnosis; 3576 (25 %) had not used any 
kind of anti-HT medication (Table 1). Compared to non-users, anti-HT medication users were older 
at diagnosis (median age 73 years) and also used more often statins and antidiabetic medication. 
During the median follow-up of 4.1 years after BCa diagnosis, a total of 5550 participants (40/100) 
died. Of these, 2948 (21/100) died of BCa.  
Among the UTUC cohort use of anti-HT drugs was also common: of 1080 participants 852 (79%) 
had used anti-HT drugs while only 228 (21 %) had not used any anti-HT medication during the 
follow-up. Anti-HT users were older at the time of cancer diagnosis and they used more often 
statins and antidiabetic medication. During the follow-up a total of 713 (66 /100) participants died, 
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of which 458 (42/100) by UTUC. The headline other treatment in Table 1 includes all other 
treatment methods except surgery in both BCa or UTUC ( cytostatic drugs, cemotherapy, 
antihormonal therapy).  
Antihypertensive drug usage before UC diagnosis 
Angiotensin-receptor (ATR) blocker use before BCa diagnosis was associated with slightly 
decreased risk of BCa death (HR: 0.80 95% CI: 0.70-0.92) (Table 2). In the intensity analyses highest 
intensity of ATR-blocker use associated with most reduction in BCa death risk (HR: 0.65 95% CI: 
0.50-0.84). Long-time (5 years or more) use of ATR-blockers was associated with statistically 
significant reduction in BCa death risk (HR: 0.63 95% CI: 0.50-0.79). On the contrary, among users 
of diuretics the risk increase for BCa death was observed in all subgroup analyses being highest 
with strongest intensity of use (HR: 1.28 95% CI: 1.13-1.44). Diuretics were associated with 
increased risk of BCa death also in lag-time analyses. 
In analysis stratified by gender beta-blockers were associated with slightly increased risk of BCa 
death in men (p for interaction = 0.003, Table 6). ATR-blockers were associated with decreased 
risk only among women (p for interaction = 0.046). Diuretics associated with increased risk of BCa 
death risk in both genders. 
Pre-diagnostic use of ATR-blockers and calcium-channel blockers were associated with slightly 
decreased risk of UTUC death although the risk differences were not statistically significant (Table 
2). In lag-time analyses no clear delayed risk associations between any anti-HT drug group and 
UTUC death was found (Table 4). 
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Post-diagnostic use of ATR-blockers was similarly associated with better BCa survival compared to 
non-users and the risk decreased in inverse association with cumulative dose and intensity of use 
(Table 3). When analysed by gender ATR-blockers associated with decreased risk of BCa death only 
among men (p for interaction = 0.004, Table 6). Also calcium-channel blockers were associated 
with reduced risk of BCa death as the intensity of use increased (HR: 0.67 95% CI: 0.52-0.86 for 367 
DDDs/ yr or more). However, such risk trend was not found for duration of calcium-channel 
blocker use (Table 5). Increased risk of BCa death by diuretics use was observed among both 
genders (Table 6). 
Highest intensity of post-diagnostic beta-blocker use associated with slightly decreased risk of BCa 
death (HR: 0.76 95% CI: 0.66-0.87). Diuretics associated with increased risk of BCa death in all 
intensity analyses but risk was highest in lowest intensity of use (HR: 1.64 95% CI: 1.48-1.81). Risk 
declined to non-significant level when intensity of use increased.  
In UTUC analyses most of the risk differences by anti-HT drug use were not statistically significant. 
Similar to BCa, high dose as well as high-intensity use of diuretics associated with worse UTUC 
survival compared to non-users.  
Subgroup analyses 
We analysed separately the association between post-diagnostic anti-HT drug use on UC death in 
four subgroups stratified by potential confounding factors. The analysis was stratified by age at 
diagnosis, tumor extent at diagnosis, comorbidities and COPD separately and use of statins. 
Subgroup analyses in BCa cohort are shown in Figures 1-5.  
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Antihypertensive drug use after the UC diagnosis 
No effect modification by age was observed for ATR-blocker use, the risk decrease was similar 
among participants younger than 73 or older. The risk of BCa death among beta-blocker users, 
however, appeared to be modified by age; the risk was increased in the younger age group only (p 
for interaction <0.001). No significant effect modification by age was observed in the UTUC cohort. 
Tumor extent at diagnosis modified the association between beta-blocker use and cancer deaths 
in both study cohorts. Users of beta-blockers had increased risk of death compared to non-users 
among participants diagnosed with localized tumor, whereas no risk association was observed for 
participants with advanced disease at diagnosis (p for interaction <0.001 for BCa and UTUC 
cohorts, respectively). 
Charlson comorbidity index did not modify the risk associations in the BCa cohort. In the UTUC 
cohort, however, beta-blockers were associated with increased risk of cancer death only among 
participants with little or no co-morbidities (p for interaction = 0.005). On the contrary, ATR-
blocker users had a decreased risk of BCa death among participants with high CCI- value (p for 
interaction < 0.001). No effect modification by CCI was observed in the BCa cohort.  
When analyzed only among COPD-diagnosed participants the risk estimates for BCa death 
declined into nonsignificant level but risk estimates among ATR-blocker users stayed decreased 
compared to non-users. When excluding COPD-participants the risk decrease among ATR-blocker 
users became statistically significant (HR: 0.81 95% CI: 0.70-0.93).  
The risk of BCa death was increased in beta-blocker users only among participants also using 
statins (p < 0.001). No effect modification by statin use was observed in the UTUC cohort. 
When stratified by year of UC diagnosis, ATR-blockers were associated with better BCa survival 
only among cases diagnosed in the 1990s (p <0.001). In UTUC cohort effect modification by 
diagnosis year could not be evaluated.  
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DISCUSSION 
To our knowledge this is the first study to compare risk of death due to urothelial cancer by 
different groups of antihypertensive drugs.  
In our BCa cohort post-diagnostic ATR-blocker use generally was associated with better BCa-
specific survival compared to non-users. The association was observed in both genders, but when 
stratified by gender among females for pre-diagnosis usage and among males for post-diagnosis 
usage. The risk decrease was dose-dependent, being inversely associated with the intensity (yearly 
dose) of ATR-blocker use. The same dose-dependence was also observed among calcium-channel 
blocker users. Similar risk trend for multiple groups of antihypertensive drugs with differing 
mechanisms of action suggests that the common indication, treatment of hypertension may have 
a prognostic role in BCa patients. Diuretics instead associated with increased risk of BCa death in 
all analyses. This is likely affected by diuretics being used also for other causes besides controlling 
hypertension, such as oedema common in advanced cancer.  
Similar risk differences were not observed in the UTUC-cohort. It has to be noted that UTUC is 
frequently managed with nephroureterectomy which often leads to renal insufficiency limiting 
medication use, for example of drugs affecting RAA-system. Therefore UTUC patients may not be 
able to use drugs affecting RAA-system which could explain more subtle risk associations 
compared to BCa cohort. However our analysis were adjusted with kidney failure so that there 
must be another explanation.  
All anti-HT drugs except beta-blockers and some diuretics such as furosemide are first-line 
treatment of hypertension in Finland. Thus, it´s not likely that patients using different groups of 
anti-HT drugs differ from each other by difficulty of hypertension. On the contrary anti-HT drugs 
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are also used to treat other diseases than hypertension like coronary artery disease and kidney 
and heart failure, which may have a confounding effect on results particularly among beta-blocker 
and diuretic users. Nevertheless, adjustment for CCI did not remove the risk increase observed 
among users of diuretics and beta-blockers.  
The strengths of our study are long follow-up time and large BCa-cohort consisting of all bladder 
cancers diagnosed in Finland between 1995-2012. Our registry-based data on medication use was 
exceptionally detailed and free of recall bias. We were able to take into account simultaneous use 
of different anti-HT drug groups and statins, NSAIDs, aspirin and antidiabetic medication and to 
adjust the analysis for primary treatment, as anti-HT drug users likely had more comorbidities 
limiting possibilities for curative-intent surgery. We also adjusted our analyses with year of 
diagnosis as cancer management has changed over time, possibly modifying the survival 
associations with anti-HT drug use.  
We didn´t have information on blood pressure level, i.e. on how well hypertension was managed, 
which may affect results if hypertension indeed was a prognostic factor. We didn´t also know 
whether anti-HT drugs purchased were actually consumed. Our information on medication use 
starts on 1995 which likely causes under estimation of pre-diagnostic medication use. Also low 
number of BCa and UTUC deaths in our data must be considered because it limits the statistical 
power in subgroup analyses increasing probability for type 2 error. We didn´t have information on 
tumour grade which may have caused confounding if anti-HT medication was associated with 
grade. We didn´t have information on socioeconomical or lifestyle factors such as physical activity 
or smoking which could have served as confounders depending on their association with 
antihypertensive medication use and urothelial cancer survival. These factors may partly explain 
12
the differing results among ATR-blocker and calcium-channel blocker users compared to other 
anti-HT drug groups. Nevertheless, selection bias shouldn´t be dose-dependent. 
In conclusion ATR- blocker use was associated with better BCa survival both in pre- and post-
diagnostic use. The association was dose-dependent. Also high-intensity use of beta-blockers and 
calcium-channel blockers associated with reduced BCa death risk which may be partly explained 
with better control of hypertension. Our study supports further studies on the association 
between ATR-blockers and BCa progression.  
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Table 1. Population characteristics. 
non-users ACE-
inhibitors 
ATR-
blockers 
beta-
blockers 
calcium-
channel 
blockers 
diuretics 
n of 
participants; 
(BCa/UTUC) 
3578/ 228 5276 / 382 2495 / 
240 
7544 / 623 3247 / 446 7176 / 516 
men 
(BCa/UTUC) 
2776/ 148 4123/ 214 1863 / 
118 
5788 /352 2451 /229 5235 / 243 
women 
(BCa/UTUC) 
802/ 80 1153 / 168 632 / 122 1753 / 271 796 / 217 1941 / 273 
median follow 
up time (IQR), 
(BCa/UTUC) 
5.2 (0-18.9) 
/ 2.5 (0-
18.0) 
5.8 (0-
18.9) / 
3 ( 0-18.9) 
6.5 (0-
18.9) / 
3.8 (0-
18.6) 
5.8 (0-
18.9) / 
2.9 (0-
18.9) 
5.7 (0-
18.9) / 
3.1 (0-
18.9) 
5.4 (0-18.9) 
/ 
2.6 (0-18.9) 
n of cancer 
deaths   (% of 
users), 
(BCa/UTUC) 
1013 
(28.3)/ 110 
(48.2) 
 954 (18) / 
139 (36.4) 
355 (14.2) 
/ 70 (29.2) 
1562 
(20.7) / 
236 (37.9) 
646 (19.9) 
/ 160 
(35.9) 
1678 (23.4) 
/ 229 (44.4) 
Age at 
diagnosis, 
median (IQR), 
(BCa/UTUC) 
67.5 (20-
102) / 
66 (29-97) 
73.2 (22-
102) / 
75 (44-96) 
71.1 (29-
98) /
74 (44-96) 
73.6 (22-
102) / 
75 (44-96) 
74.2 (22-
101) / 
76 (44-99) 
74.8 (22-
104) 
stage, BCa; 
n(%) 
local 2071 (57.9) 3386 
(64.2) 
1627 
(65.2) 
4739 
(62.8) 
2046 
(63.0) 
4354 (60.7) 
advanced 588 (16.4) 534 (10.1) 249 (10.0) 834 (11.1) 329 (10.1) 841 (11.7) 
unknown 917 (25.6) 1356 
(25.7) 
619 (24.8) 1971 
(26.1) 
872 (26.9) 1981 (27.6) 
stage, UTUC; 
n(%) 
local 86 (37.7) 163 (42.7) 116 (48.3) 260 (41.7) 193 (43.3) 209 (40.5) 
advanced 105 (46.0) 138 (36.1) 79 (32.9) 224 (36.0) 149 (33.4) 191 (37.0) 
unknown 37(16.2) 81 (21.2) 45 (18.8) 139 (22.3) 104 (23.3) 116 (22.5) 
primary care 
of UC, n (%) 
surgery in BCa 1739 (48.6) 2717 
(51.5) 
1336 
(53.5) 
3817 
(50.6) 
1622 
(50.0) 
3443 (48) 
radical 
cystectomy in 
BCa 
528 (14.8) 506 (9.6) 244 (9.8) 699 (9.3) 283 (8.7) 614 (8.6) 
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other 
treatment in 
BCa 
1030 (28.8) 1451 
(27.5) 
623 (25.0) 2164 
(28.7) 
952 (29.3) 2145 (29.9) 
surgery in 
UTUC 
181 (79.4) 288 (75.4) 189 (78.8) 476 (76.4) 341 (76.5) 385 (74.6) 
radical nephro-
ureterectomy 
in UTUC 
138 (60.5) 243 (63.6) 159 (66.3) 394 (63.2) 283 (63.5) 302 (58.5) 
other 
treatment in 
UTUC 
64 (28.0) 81 (21.2) 41 (17.1) 135 (21.7) 97 (21.7) 114 (22.1) 
Statin use, n 
(%)(BCa/UTUC) 
535 (15) / 
37 (16) 
2934 
(55.6) / 
234 (61.3) 
1494 
(59.9) / 
150 (62.5) 
3943( 
52.3) / 
333 (53.5) 
1699 
(52.3) / 
238 (53.4) 
3211 (44.7) 
/ 
227 (44.0) 
Antidiabetic 
medication 
use; n 
(%)(BCa/UTUC) 
237 (6.6) / 
10 (4.4) 
1810 
(34.3) / 
116 (30.4) 
816 (32.7) 
/ 
71 (29.6) 
2031( 
26.9) / 
135 (21.7) 
933 (28.7) 
/ 
104 (23.3) 
2025 (28.2) 
/ 
121 (23.4) 
radiotherapy 
(n; no 
information) 
444 (835) 566 (1161) 230 (560) 867 (1641) 362 (711) 890 (1671) 
chemotherapy 
(n; no 
information) 
746 (777) 1089 
(1054) 
521 (509) 1511 
(1494) 
624 (649) 1417 (1512) 
BCa= Bladder cancer, UTUC= Upper tract urothelial carcinoma, UC=urothelial cancer, IQR=interquartile 
range.  
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Table 2. Risk of urothelial cancer death by antihypertensive drug use before diagnosis of UC. 
Risk of BCa death Risk of UTUC death 
Drug group n of 
users/BCa 
deaths 
HR (95% 
CI)age-
adjusted 
HR (95% 
CI)multiavariable 
adjusted* 
n of 
users/UTUC 
deaths 
HR (95% CI)age-
adjusted
HR (95% 
CI)multiavariable 
adjusted*
ACE 
inhibitors 
3450/ 751 0.89 
(0.81-
0.97) 
1.03 (0.94-
1.13) 
267 / 123 1.14 (0.90-1.43) 1.48 (1.00-
2.21) 
ATR-
blockers 
 1409 /258 0.76 
(0.67-
0.87) 
0.80 (0.70-
0.92) 
144 / 52 0.78 (0.58-1.06) 0.87 (0.54-
1.39) 
Average 
yearly dose 
of ATR-
blocker 
(DDDs/year) 
0-245 475 / 111 0.97 
(0.80-
1.18) 
0.92 (0.76-
1.12) 
49 / 20 1.02 (0.65-1.62) 1.36 (0.63-
2.95) 
245-392 465 /83 0.71 
(0.57-
0.89) 
0.80 (0.64-
1.00) 
47 / 16 0.67 (0.40-1.11) 1.13 (0.50-
2.58) 
392 467 / 63 0.58 
(0.45-
0.75) 
0.65 (0.50-
0.84) 
48/ 16 0.69 (0.41-1.15) 0.63 (0.33-
1.19) 
Beta-
blockers 
5327 /1211 0.85 
(0.78-
0.91) 
1.03 (0.95-
1.12) 
448 / 189 0.91 (0.73-1.12) 1.15 (0.76-
1.75) 
Calcium-
channel 
blockers 
754/180 0.87 
(0.79-
0.96) 
0.98 (0.88-
1.08) 
281 / 116 0.86 (0.68-1.09) 0.77 (0.52-
1.15) 
Diuretics 4426 /1121 1.20 
(1.10-
1.31) 
1.13 (1.04-
1.24) 
311 / 149 1.30 (1.04-1.63) 1.20 (0.78-
1.83) 
*= calculated cox regression model with adjustments of age, radical surgery , tumor extent, CCI, year of 
diagnosis, statin, NSAID, aspirin and antidiabetic medication use, kidney failure, COPD and cytostatic drugs. 
UC= Urothelial cancer, BCa= Bladder cancer, UTUC= Upper tract urothelial carcinoma, DDD= Defined Daily 
Dose 
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Table 3. Risk of bladder cancer death by cumulative amount, duration and average yearly dose of ATR- 
blocker use after diagnosis. 
Amount of use 
(DDDs) 
n of users/BCa 
deaths 
Riski of BCa death 
HR (95%CI) age-
adjusted
Risk of BCa death 
HR (95% CI) 
multiavariable adjusted*
0-490 641 / 148 0.82 (0.70-0.97) 0.90 (0.76-1.06) 
490-1764 641 /91 0.59 (0.47-0.73) 0.73 (0.59-0.91) 
1764 657 / 23 0.51 (0.33-0.78) 0.60 (0.39-0.91) 
Duration of use 
(years) 
n of users/BCa 
deaths 
Riski of BCa death 
HR (95%CI) age-
adjusted 
Risk of BCa death 
HR (95% CI) 
0-2 601 /153 0.69 (0.60-0.80) 0.80 (0.69-0.93) 
2-4 245 / 25 0.71 (0.51-1.00) 0.85 (0.60-1.18) 
4 566 /24 0.74 (0.49-1.3) 0.80 (0.52-1.22) 
Average yearly 
dose (DDDs/year) 
n of users/BCa 
deaths 
Riski of BCa death 
HR (95%CI) age-
adjusted 
Risk of BCa death 
HR (95% CI) 
0-259 634 / 135 1.04 (0.87-1.24) 1.04 (0.87-1.24) 
259-504 630/ 98 0.67 (0.54-0.82) 0.79 (0.64-0.97) 
504 632/34 0.35 (0.26-0.48) 0.48 (0.35-0.65) 
*= calculated cox regression model with adjustments of age, radical surgery , tumor extent, CCI, year of 
diagnosis, statin, NSAID, aspirin and antidiabetic medication use, kidney failure, COPD and cytostatic drugs. 
UC= Urothelial cancer, BCa= Bladder cancer, UTUC= Upper tract urothelial carcinoma, DDD= Defined Daily 
Dose 
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Table 4. Risk of UC death by antihypertensive drug use after UC diagnosis. 
Risk of BCa death Lag-time 
Drug group n of users/BCa 
deaths 
HR (95% 
CI)age-adjusted
HR (95% 
CI)multiavariable 
adjusted (*) 
1yr 3yrs 5yrs 
ACE inhibitors 377/19 0.80 (0.73-
0.88) 
0.99 (0.90-
1.08) 
1.06 
(0.96-
1.17) 
0.99 
(0.88-
1.00) 
0.99 
(0.88-
1.10) 
ATR blockers 177/ 4 0.70 (0.61-
0.79) 
0.81 (0.71-
0.92) 
0.82 
(0.71-
0.93) 
0.72 
(0.61-
0.85) 
0.72 
(0.61-
0.85) 
Beta-blockers 500/ 20 0.89 (0.82-
0.96) 
1.05 (0.97-
1.13) 
1.09 
(1.01-
1.18) 
1.08 
(0.99-
1.19) 
1.08 
(1.00-
1.19) 
Calcium-channel 
blockers 
127/ 3 0.85 (0.76-
0.95) 
0.95 (0.85-
1.06) 
0.93 
(0.83-
1.05) 
0.92 
(0.81-
1.05) 
0.92 
(0.81-
1.05) 
 Diuretics 490 / 30 1.53 (1.41-
1.66) 
1.42 (1.31-
1.54) 
1.24 
(1.14-
1.35) 
1.21 
(1.10-
1.34) 
1.21 
(1.10-
1.34) 
Risk of UTUC death Lag-time 
Drug group n of users/BCa 
deaths 
HR (95% 
CI)age-adjusted 
HR (95% 
CI)multiavariable 
adjusted (*)
1yr 3yrs 5yrs 
ACE inhibitors 179 / 74 0.87 (0.67-
1.12) 
1.20 (0.79-
1.85) 
1.23 
(0.81-
1.87) 
1.39 
(0.92-
2.12) 
1.45 
(0.95-
2.11) 
ATR blockers 130 / 49 0.81 (0.60-
1.11) 
1.03 (0.65-
1.65) 
1.07 
(0.66-
1.74) 
1.08 
(0.62-
1.87) 
0.88 
(0.41-
1.88) 
Beta-blockers 410 / 178 0.96 (0.78-
1.18) 
1.06 (0.70-
1.59) 
1.06 
(0.71-
1.59) 
1.02 
(0.70-
1.49) 
1.09 
(0.74-
1.59) 
Calcium-channel 
blockers 
238 / 104 1.00 (0.80-
1.25) 
0.93 (0.62-
1.40) 
0.93 
(0.62-
1.40) 
0.90 
(0.59-
1.39) 
1.05 
(0.66-
1.68) 
 Diuretics 285 / 146 1.46 (1.17-
1.83) 
1.47 (0.95-
2.28) 
1.28 
(0.82-
2.02) 
1.44 
(0.91-
2.29) 
1.32 
(0.81-
2.15) 
*= calculated cox regression model with adjustments of age, radical surgery , tumor extent, CCI, year of 
diagnosis, statin, NSAID, aspirin and antidiabetic medication use, kidney failure, COPD and cytostatic drugs. 
UC= Urothelial cancer, BCa= Bladder cancer, UTUC= Upper tract urothelial carcinoma, DDD= Defined Daily 
Dose 
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Table 5. Risk of BCa death by cumulative amount, duration and average yearly dose of calcium-channel 
blocker use after diagnosis. 
Amount of use 
(DDDs) 
n of users/BCa 
deaths 
Riski of BCa death 
HR (95%CI) age-
adjusted
Risk of BCa death 
HR (95% CI) 
multiavariable adjusted*
0-333 690 / 210 1.04 ( 0.90-1.21) 1.14 (0.99-1.33) 
333-1200 687/ 127 0.67 (0.55-0.82) 0.82 (0.67-1.00) 
1200 691 / 37 0.48 (0.28-0.81) 0.56 (0.33-0.94) 
Duration of use 
(years) 
n of users/BCa 
deaths 
Riski of BCa death 
HR (95%CI) age-
adjusted 
Risk of BCa death 
HR (95% CI) 
0-1 686 /207 0.83 (0.72-0.95) 0.93 (0.81-1.07) 
1-4 814 / 146 0.93 (0.78-1.12) 1.03 (0.86-1.23) 
4 537 /21 0.69 (0.45-1.08) 0.73 (0.47-1.13) 
Average yearly 
dose (DDDs/year) 
n of users/BCa 
deaths 
Riski of BCa death 
HR (95%CI) age-
adjusted 
Risk of BCa death 
HR (95% CI) 
0- 196 667/ 155 1.20 (1.02-1.41) 1.26 (1.06-1.48) 
196- 367 624 / 113 0.69 (0.56-0.85) 0.91 (0.73-1.13) 
367 678 / 78 0.61 (0.48-0.78) 0.67 (0.52-0.86) 
*= calculated cox regression model with adjustments of age, radical surgery , tumor extent, CCI, year of 
diagnosis, statin, NSAID, aspirin and antidiabetic medication use, kidney failure, COPD and cytostatic drugs. 
UC= Urothelial cancer, BCa= Bladder cancer, UTUC= Upper tract urothelial carcinoma, DDD= Defined Daily 
Dose 
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Table 6. Risk of UC death before and after diagnosis by antihypertensive drug use. Separated analyses by 
gender (men/women). 
Drug 
group  
used 
Risk of BCa death in men Risk of BCa death in women 
Before BCa 
diagnosis 
After BCa diagnosis Before BCa diagnosis After BCa diagnosis 
HR 
(95% 
CI)age-
adjusted
HR (95% 
CI)multiavariable 
adjusted*
HR 
(95% 
CI)age-
adjusted
HR (95% 
CI)multiavariable 
adjusted*
HR (95% 
CI)age-
adjusted
HR (95% 
CI)multiavariable 
adjusted*
HR (95% 
CI)age-
adjusted
HR (95% 
CI)multiavariable 
adjusted*
ACE 
inhibitors 
0.94 
(0.84-
1.05) 
1.13 (1.01-
1.27) 
0.81 
(0.72-
0.90) 
1.00 (0.90-
1.12) 
0.85 
(0.71-
1.00) 
0.87 (0.74-
1.04) 
0.81 
(0.67-
0.96) 
0.92 (0.77-
1.10) 
ATR 
blockers 
0.76 
(0.65-
0.90) 
0.84 (0.71-
1.00) 
0.67 
(0.57-
0.78) 
0.79 (0.67-
0.93) 
0.76 
(0.60-
0.95) 
0.76 (0.60-
0.96) 
0.74 
(0.59-
0.93) 
0.82 (0.66-
1.04) 
Beta-
blockers 
0.91 
(0.83-
1.00) 
1.18 (1.07-
1.30) 
0.93 
(0.85-
1.02) 
1.14 (1.04-
1.25) 
0.74 
(0.64-
0.85) 
0.80 (0.69-
0.92) 
0.81 
(0.71-
0.93) 
0.89 (0.78-
1.03) 
Calcium-
channel 
blockers 
0.82 
(0.73-
0.93) 
0.96 (0.85-
1.09) 
0.81 
(0.71-
0.93) 
0.91 (0.80-
1.05) 
0.98 
(0.83-
1.16) 
1.01 (0.85-
1.19) 
0.93 
(0.77-
1.12) 
1.05 (0.86-
1.27) 
 Diuretics 1.14 
(1.02-
1.27) 
1.05 (0.94-
1.17) 
1.67 
(1.51-
1.84) 
1.54 (1.40-
1.71) 
1.19 
(1.03-
1.37) 
1.19 (1.03-
1.38) 
1.21 
(1.05-
1.39) 
1.18 (1.03-
1.36) 
Risk of UTUC death in men Risk of UTUC death in women 
Drug 
group 
used 
Before UTUC 
diagnosis 
After UTUC 
diagnosis 
Before UTUC 
diagnosis 
After UTUC diagnosis 
HR 
(95% 
CI)age-
adjusted
HR (95% 
CI)multiavariable 
adjusted*
HR 
(95% 
CI)age-
adjusted
HR (95% 
CI)multiavariable 
adjusted*
HR (95% 
CI)age-
adjusted
HR (95% 
CI)multiavariable 
adjusted*
HR (95% 
CI)age-
adjusted
HR (95% 
CI)multiavariable 
adjusted*
ACE 
inhibitors 
1.14 
(0.83-
1.57) 
1.66 (0.90-
3.06) 
0.86 
(0.60-
1.22) 
1.49 (0.79-
2.81) 
1.16 
(0.83-
1.62) 
1.55 (0.82-
2.93) 
0.86 
(0.58-
1.27) 
1.06 (0.56-
1.99) 
ATR 
blockers 
0.94 
(0.61-
1.45) 
0.83 (0.40-
1.72) 
0.78 
(0.50-
1.24) 
0.91 (0.43-
1.93) 
0.69 
(0.45-
1.06) 
0.92 (0.46-
1.84) 
0.85 
(0.56-
1.29) 
1.30 (0.67-
2.54) 
Beta-
blockers 
0.69 
(0.52-
0.92) 
1.98 (1.05-
3.73) 
0.82 
(0.62-
1.09) 
1.14 (0.63-
2.06) 
1.25 
(0.91-
1.73) 
0.75 (0.39-
1.45) 
1.14 
(0.83-
1.56) 
1.19 (0.64-
2.24) 
Calcium-
channel 
blockers 
0.91 
(0.65-
1.26) 
0.65 (0.35-
1.21) 
1.05 
(0.77-
1.45) 
0.74 (0.40-
1.38) 
0.75 
(0.53-
1.06) 
1.01 (0.55-
1.85) 
0.97 
(0.70-
1.34) 
1.12 (0.62-
2.04) 
 Diuretics 1.51 
(1.10-
2.08) 
1.78 (0.96-
3.30) 
1.59 
(1.17-
2.18) 
1.51 (0.75-
3.04) 
1.14 
(0.82-
1.59) 
0.93 (0.49-
1.76) 
1.36 
(0.98-
1.90) 
1.23 (0.64-
2.34) 
*= calculated cox regression model with adjustments of age, radical surgery , tumor extent, CCI, year of 
diagnosis, statin, NSAID, aspirin and antidiabetic medication use, kidney failure, COPD and cytostatic drugs. 
UC= Urothelial cancer, BCa= Bladder cancer, UTUC= Upper tract urothelial carcinoma, DDD= Defined Daily 
Dose 
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Figure 1. Risk of BCa death among ACE-inhibitor users. Stratified analyses with age 
at diagnosis, tumor extent, CCI, statin use and year of BCa diagnosis. 
Figure 2. Risk of BCa death among ATR-blocker users. Stratified analyses with age 
at diagnosis, tumor extent, CCI, statin use and year of BCa diagnosis. 
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Figure 3. Risk of BCa death among beta-blocker users. Stratified analyses with age 
at diagnosis, tumor extent, CCI, statin use and year of BCa diagnosis. 
Figure 4. Risk of BCa death among calcium-channel blocker users. Stratified analyses 
with age at diagnosis, tumor extent, CCI, statin use and year of BCa diagnosis. 
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Figure 5. Risk of BCa death among diuretic users. Stratified analyses with age at diagnosis, 
tumor extent, CCI, statin use and year of BCa diagnosis. 
0
0,5
1
1,5
2
2,5
HR
Diuretics use
< 75
≥ 75
24
